Do it for the kids! Participate with your family and friends in the Scotiabank Charity Challenge 5K or Half Marathon with Team Cassie & Friends! Proceeds support research and programs for kids with juvenile arthritis and other rheumatic diseases and their families. Free kid registrations, activities and prizes. If you are unable to make the run, you can still participate by cheering for the team on along the run/walk route!
Today is the last day to register online! For more information about the event and to register online, please visit www.canadarunningseries.com and register with the charity code 16VCASSIE.
About Juvenile Arthritis
A press release issued on June 9, 2016 by the European League Against Rheumatism Annual Congress highlighted a study that suggest depression is linked to disease activity and disability in adolescents with juvenile idiopathic arthritis. Below is a copy of the press release:
European League Against Rheumatism Annual Congress
London, United Kingdom, 8-11 June 2016
DEPRESSION LINKED TO DISEASE ACTIVITY AND DISABILITY IN ADOLESCENTS WITH ARTHRITIS
Study reinforces the importance of psychological assessment and support
London, United Kingdom, 9 June 2016: The results of a study presented today at the European League Against Rheumatism Annual Congress (EULAR 2016) confirmed a clear association between depression symptom severity and the level of disease activity and disability in adolescent patients with juvenile inflammatory arthritis (JIA). These findings highlight the importance of psychological health assessment for adolescents with JIA and underline the need for psychological support to be fully integrated into their routine care.
(Please click on the map for more information about the provincial drug formulary updates.)
The latest provincial listings, at your fingertips
Good news for people living with autoimmune arthritis in Canada!
Arthritis Consumer Experts (ACE) maps out the latest news for you: Read about the important changes to provincial drug formularies and what it means for Canadians living with autoimmune arthritis. The changes covered in this update affect people living with rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and juvenile idiopathic arthritis (JIA). Continue reading
BC PharmaCare is looking for your input on canakinumab for the treatment of systemic juvenile idiopathic arthritis (sJIA)
Canakinumab (Ilaris®) is now being considered for coverage under the British Columbia Ministry of Health’s PharmaCare program. By filling out a questionnaire on a website called Your Voice, you can provide feedback about canakinumab for the treatment of sJIA.
You can give input if you are a B.C. resident and have sJIA, a caregiver to someone with sJIA, or if your group represents people who live with sJIA.
The input is reviewed by the Drug Benefit Council, which then gives recommendations on whether a medication should be covered, and how, by BC PharmaCare. BC PharmaCare then makes a decision based on those recommendations and available resources. Policies and plans already in place also factor in the decision making process. Continue reading
A team of researchers has developed Canada’s first set of systematic measures for tracking how well or poorly health systems are doing in providing services to people who have inflammatory arthritis (IA), a potentially crippling disease that is on the rise in Canada.
The researchers developed six key measures for gauging access to specialist care and initiation of treatment for people with IA, a disease grouping that includes rheumatoid arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, and psoriatic arthritis. The work is described in March issue of The Journal of Rheumatology.
People who receive early diagnosis and start of treatment have a better chance of responding well and avoiding permanent joint damage from rheumatoid arthritis (RA), the most common form of IA. There is a growing body of evidence that early detection and treatment are also crucial to good outcomes for people who have other types of IA. Continue reading
Quebec’s INESSS wants to hear your comments on apremilast (Otezla®) and adalimumab (Humira®)
Do you have psoriatic arthritis or juvenile arthritis or care for someone who does? We need your valuable input.
The National Institute of excellence in health and social services (INESSS) in Quebec is asking health professionals, consumers and patients, and patient groups to submit their comments about apremilast (Otezla®) for the treatment of psoriatic arthritis and adalimumab (Humira®) for the treatment of juvenile arthritis. These medications are being evaluated as part of the 2016 update to the List of Medications. Continue reading